FILE PHOTO: Signage is seen outside of FDA headquarters in White Oak, Maryland (Reuters) -Bluebird bio said on Monday it has agreed to sell its priority review voucher for $103 million if it gets the ...
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that new and updated data from its lentiviral vector (LVV) gene addition programs in patients with sickle cell ...
The approval Friday of Bluebird Bio’s gene therapy for sickle cell disease should have been a momentum-swinging achievement for the long-struggling biotech. Instead, the company mispriced its new drug ...
The FDA has approved bluebird bio’s lovotibeglogene autotemcel (lovo-cel), marketed as Lyfgenia, as a treatment for sickle cell disease (SCD) in patients aged 12 years and older. 1 The therapy ...
In a historic move, the Food and Drug Administration approved two gene therapies to treat sickle cell disease (SCD) Friday morning. The FDA approved Vertex Pharmaceuticals and CRISPR Therapeutics’ ...
The 2025 meeting of the American Society of Hematology features some of the newest developments in blood cancers and rare ...
Adding erythropoietin to hydroxyurea treatment could significantly improve quality of life for patients with sickle cell ...
Both new FDA-approved medicines offer a potential cure, but they will come with a hefty price tag and it will be years before their long-term effects are clear. Sickle cell disease, a painful ...
Sickle cell anemia causes sickle-shaped cells to block blood flow to the lungs, leading to acute chest syndrome. Common treatment methods involve oxygen supplementation and pain management. Sickle ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback